The High Court agreed with Eisai Limited that guidance issued by NICE in relation to the use of AChEI drugs for the treatment of Alzheimer’s disease was discriminatory, in particular in relation to people with disabilities, learning difficulties or for those who are not fluent in English or the language in which the relevant tests are applied. It ordered NICE to amend the guidance accordingly to comply with its duties and obligations under antidiscriminatory laws. The High Court decided however, that there was no procedural unfairness or irrationality in NICE’s decision making process. On 1 October, Eisai applied to the Court of Appeal for permission to appeal this ruling in relation to the process by which the NICE reached its decision on the costeffectiveness of drugs in the early stages of Alzheimer’s disease. For further information, see [2007] EWHC 1941 (Admin)